Dermata Therapeutics (DRMAW) Competitors $0.02 0.00 (-9.87%) Closing price 10/24/2025 03:30 PM EasternExtended Trading$0.02 +0.00 (+0.48%) As of 10/24/2025 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsSEC FilingsShort InterestTrendsBuy This Stock DRMAW vs. ATNFW, LBPSW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, BCTXW, CALA, and CELUWShould you be buying Dermata Therapeutics stock or one of its competitors? The main competitors of Dermata Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), Calithera Biosciences (CALA), and Celularity (CELUW). These companies are all part of the "pharmaceutical products" industry. Dermata Therapeutics vs. Its Competitors 180 Life Sciences 4D pharma Ainos Alvotech Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Calithera Biosciences Celularity 180 Life Sciences (NASDAQ:ATNFW) and Dermata Therapeutics (NASDAQ:DRMAW) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations. Does the media favor ATNFW or DRMAW? In the previous week, Dermata Therapeutics had 1 more articles in the media than 180 Life Sciences. MarketBeat recorded 1 mentions for Dermata Therapeutics and 0 mentions for 180 Life Sciences. Dermata Therapeutics' average media sentiment score of 1.91 beat 180 Life Sciences' score of 0.00 indicating that Dermata Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment 180 Life Sciences Neutral Dermata Therapeutics Very Positive Is ATNFW or DRMAW more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A Dermata Therapeutics N/A N/A N/A Which has better valuation and earnings, ATNFW or DRMAW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/ADermata TherapeuticsN/AN/AN/AN/AN/A SummaryDermata Therapeutics beats 180 Life Sciences on 2 of the 2 factors compared between the two stocks. Get Dermata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DRMAW and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRMAW vs. The Competition Export to ExcelMetricDermata TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$220.37M$6.21B$10.81BDividend YieldN/A3.81%5.72%4.80%P/E RatioN/A3.2831.6030.98Price / SalesN/A5,399.00595.06133.64Price / CashN/A13.1937.2561.86Price / BookN/A90.1312.056.61Net IncomeN/A-$90.99M$3.34B$277.10M7 Day PerformanceN/A0.72%1.94%2.57%1 Month PerformanceN/A5.76%6.88%3.20%1 Year PerformanceN/A488.85%56.06%33.22% Dermata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRMAWDermata TherapeuticsN/A$0.02-9.9%N/A+153.0%$0.00N/A0.008Positive NewsShort Interest ↓Gap DownATNFW180 Life SciencesN/A$0.05+10.9%N/A+355.7%$0.00N/A0.007Gap DownLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAIMDWAinosN/A$0.15+7.0%N/AN/A$0.00$110.87K0.0040Gap DownALVOWAlvotechN/A$1.95+5.4%N/A-44.0%$0.00$560.10M0.004Gap UpACABWAtlantic Coastal Acquisition Corp. IIN/A$0.02-22.1%N/AN/A$0.00N/A0.0015Gap UpBFRIWBiofronteraN/A$0.10-0.1%N/A+149.0%$0.00$39.19M0.0070BTMDWbioteN/A$0.01-3.6%N/A-97.6%$0.00$199.07M0.00N/AGap UpHigh Trading VolumeBCTXWBriaCell TherapeuticsN/A$0.06+1.9%N/A-82.0%$0.00N/A0.008Negative NewsCALACalithera Biosciences0.5254 of 5 starsN/AN/AN/A$0.00N/A0.0060CELUWCelularityN/A$0.03+45.4%N/A+58.5%$0.00$44.59M0.00220Positive NewsGap Down Related Companies and Tools Related Companies ATNFW Competitors LBPSW Competitors AIMDW Competitors ALVOW Competitors ACABW Competitors BFRIW Competitors BTMDW Competitors BCTXW Competitors CALA Competitors CELUW Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRMAW) was last updated on 10/26/2025 by MarketBeat.com Staff From Our PartnersU.S. Government Sparking Crypto RallyMissed Bitcoin when it was $100? You’re not alone. Crypto runs in cycles—and the next one is already underw...Crypto 101 Media | SponsoredIt’s Time to Buy “the NVIDIA of Quantum Computing”Yahoo Finance wrote that investing in quantum computing could... "Lead to life-changing returns... and make...Brownstone Research | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuy the dip? Here’s my #1 gold stock“The most obvious opportunity in gold stocks I’ve seen in my career” While everyone is distracted by gold’s...Golden Portfolio | SponsoredThe strategy that wins no matter where the market goesJoel and Adam have built a crypto trading system with a 93% win rate — even through volatile, sideways markets...Crypto Swap Profits | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you want a way to generate consistent market income without chasing volatile AI stocks or complex crypto tr...Base Camp Trading | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
